<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4600">
  <stage>Registered</stage>
  <submitdate>11/06/2014</submitdate>
  <approvaldate>11/06/2014</approvaldate>
  <nctid>NCT02226302</nctid>
  <trial_identification>
    <studytitle>Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer</studytitle>
    <scientifictitle>Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer</scientifictitle>
    <utrn />
    <trialacronym>FETCH</trialacronym>
    <secondaryid>FETCH</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometrial Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Female Group 2 - Females with BMI &gt;30 kg/m2 who are having a hysterectomy for benign conditions

Females Group 1 - Females with BMI &lt;30 kg/m2 who are having a hysterectomy for benign conditions

Males - 2 males with BMI &lt;30 kg/m2 and 2 males with BMI &gt;30 kg/m2

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Identify estrogen-response genes in endometrial cancer - Omental fat will be collected from 6 lean patients, 6 obese patients and 4 controls (male patients) and co-cultured with endometrial cancer cell lines</outcome>
      <timepoint>Baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Examine how expression of estrogen response genes are altered in obesity - Compare gene response in tissue from lean and obese individuals</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age 18-80 years

          -  Any patient having abdominal surgery (Laparoscopic or open technique) for benign
             conditions

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients must have adequate:

          -  Hematologic function: Neutrophils = 1.5 x 109/L and platelets = 100 x 109/L

          -  Renal function: serum creatinine = ULN or estimated glomerular filtration rate (eGFR)
             [CKD-EPI Formula] = 60 mL/min

          -  Hepatic function: serum bilirubin = 1.5 x ULN and AST = 2.5 x ULN and ALT= 2.5 x ULN

          -  Physically able to undergo surgery

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Confirmed gynaecological malignancy

          -  Contraindications and/or unfit for Surgery: serious concomitant systemic disorders
             incompatible with the study (at the discretion of the investigator);

          -  Patients who are pregnant or lactating

          -  Serious illness or medical condition but not limited to, ongoing or active infection,
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
             (patients with stable AF are eligible), or psychiatric illness/social situations that
             would limit compliance with study requirements.

          -  Patients with disseminated intra-peritoneal malignancy or suspected ovarian cancer

          -  HIV positive

          -  Previous bariatric surgery</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>16</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Queen Elizabeth II Jubilee Hospital - Coopers Plains</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <postcode>4108 - Coopers Plains</postcode>
    <postcode>4029 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Queensland Centre for Gynaecological Cancer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Queensland Institute of Medical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Brisbane and Women's Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective is to develop an organotypic model to assess the effects of obesity on the
      expression and methylation status of estrogen-responsive genes in endometrial cancer. Omental
      fat samples will be removed from participants during surgery and these fat samples will be
      used in laboratory analyses.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02226302</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Donal Brennan</name>
      <address>Queensland Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Donal Brennan</name>
      <address />
      <phone>(07) 3646 8111</phone>
      <fax />
      <email>Donal.brennan@health.qld.gov.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>